Notably, while the use of trametinib (MEK inhibitor) leads to alopecia in about 13% of cases, dual BRAF/MEK inhibition with vemurafenib/cobimetinib or dabrafenib/trametinib leads to alopecia in 13% and 6% of cases, respectively [13,14]. The gene discussed is MAP2K7; the disease is alopecia.